source
- Scribe secures $129M in a rare gene editing IPOThe startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most other biotechs that have gone public in 2026.BioPharma Dive · 5d ago↗ source
- FDA panel endorses broader use of certain peptidesIn a victory for Robert F. Kennedy Jr.’s “MAHA” agenda, panelists narrowly recommended broader use of six of the seven peptides up for consideration despite a lack of substantive evidence supportin…BioPharma Dive · 5d ago↗ source
- Updated: FDA adcomm backs popular wellness peptides, despite staff concernsAn FDA advisory committee voted to recommend expanding access to popular peptides used by health and wellness enthusiasts for repairing muscles, healing injuries, boosting metabolism and reducing i…